Form 4: FMR LLC Sells Shares in Sana Biotechnology, Inc.

FMR LLC, a significant shareholder of Sana Biotechnology, Inc., has sold a substantial number of common stock shares across multiple transactions on January 8, 2025.

Summary

• FMR LLC, through its various entities, sold a total of 289,912 shares of Sana Biotechnology, Inc. common stock on January 8, 2025.
• The sales were executed in multiple transactions at weighted average prices ranging from $6.05 to $7.26 per share.
• The transactions involved sales of 100,000 shares at an average price of $6.11, 25,000 shares at an average price of $6.50, and 164,912 shares at an average price of $6.71, and 1,000 shares at $7.26.
• Following these transactions, FMR LLC's indirect beneficial ownership of Sana Biotechnology common stock decreased to 4,541,511 shares through F-Prime Capital Partners Life Sciences Fund VI LP and 61 shares through FMR Capital, Inc.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the large sale of shares by a major shareholder, which could indicate a lack of confidence in the company's short-term prospects.

Negatives

• FMR LLC, a major shareholder, has reduced its stake in Sana Biotechnology, Inc. through these sales.

Risks

• Continued selling pressure from major shareholders like FMR LLC could negatively impact Sana Biotechnology's stock price.
• The multiple transactions at varying prices may indicate a lack of conviction in the stock's short-term performance by FMR LLC.

Management Comments

• The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the biotechnology sector where large institutional investors often adjust their positions.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies, including those in the biotechnology sector.
• The size of the transaction is significant, but not unusual for a large institutional investor like FMR LLC.
• Other large institutional investors in the biotechnology space, such as BlackRock or Vanguard, also regularly file similar forms when adjusting their positions.

Stakeholder Impact

• The share sale could negatively impact the share price, affecting current shareholders.
• The reduced stake by a major investor may raise concerns among other investors.

Key Dates

Keywords

FMR LLC, Sana Biotechnology, share sale, stock transaction, beneficial ownership, F-Prime Capital Partners, insider trading